

Erlotinib OPTIMAL, CTONG-0802

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Less serious and disabling adverse events observed

Other adjustments



Erlotinib OPTIMAL, CTONG-0802

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
 Therapeutic Indication: Locally advanced or metastatic NSCLC with EGFR activating mutations
 Experimental Arm: Erlotinib
 Control Arm: Carboplatin gemcitabine



